CVR Medical Corp. Plans Addition to Board of Directors

Vancouver, British Columbia–(Newsfile Corp. – February 2, 2021) – CVR Medical Corp. (TSXV: CVM) (OTC: CRRVF) (“CVR Medical” or the “Company” or “we“) a Canadian listed and US based healthcare company in the medical device market intends to diversify its’ Directors which is subject to approval at the Annual Shareholders’ Meeting. Harvey H. McKenzie is a (Life Member) Chartered Professional Accountant (CPA-CA), granted by the Chartered Professional Accountants of Ontario will be an advisory consultant for CVR Medical and has agreed to a nomination to the Board of Directors. Mr. McKenzie’s principal occupation is the provision of consulting services primarily in financial reporting areas. Mr. McKenzie has over 40 years’ experience in a variety of industries, with specific expertise in financial services. He has a record of achievement as a hands-on Chief Financial Officer, General Manager, Treasurer with excellent credit assessment and IT skills, and Director of foreign entities. Mr. McKenzie has strong interpersonal skills that complement his financial acumen, enabling him to establish outstanding client relationships and rapport with all levels of staff, bankers and regulatory bodies.

Harvey H. McKenzie has extensive corporate governance experience with TSX, OTC and AIM publicly listed companies, including both management and Directorship positions. He has extensive knowledge of the preparation of consolidated financial reporting of global entities, M&A activities, Investor Relations and Insurance/Risk Management. Harvey also has valuable experience in Initial Public Offerings (IPO) and fundraising. Harvey brings comprehensive financial expertise to CVR Medical and upon his appointment he will become Chair of the Audit Committee.

About CVR Medical:

CVR Medical Corp. is a healthcare company that operates in the medical device industry focused on the commercialization of its disruptive, proprietary Carotid Stenotic Scan device (“CSS“). The CSS is a diagnostic tool that encompasses subsonic, infrasonic, and low frequency sound wave analysis technology. The CSS is a patented device designed to detect and measure carotid arterial stenosis. CVR Medical’s shares are listed on the OTC under the symbol “CRRVF”. The Company is listed for trading under the symbol “CVM”. Additional information regarding the Company can be found in our recent filings with the SEDAR as well as the information maintained on our website at www.cvrmed.com

ON BEHALF OF THE BOARD:
(signed) Paul Blunden, M.D.
President & Director, interim CFO

For further information contact:
Paul Blunden, M.D., President/Director and interim CFO
Email: info@cvrmed.com

This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to: trading on and dialogue with the Exchange, communications and negotiations with CVR Global, dialogue with certain advisors, the Proposed Restructuring, the License Agreement, the Review, certain corporate and securities law requirements, raising capital and potential litigation. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management’s current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a failure or material setback in the Company satisfying the remaining conditions outlined by the TSX-V; (2) a failure of the Company to raise sufficient capital to relaunch the Company; (3) an inability to complete the Proposed Restructuring with CVR Global: (4)a downturn in general economic conditions in North America and internationally; (5)the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine; (6) a change in health regulations; (7) any number of events or causes which may delay or cease commercialization and development of the CSS Device; (8) the risk that the Company does not execute its business plan; (9) the risk of litigation between the Company and certain shareholders and the risk of litigation generally; (10) an inability to retain key employees; (11) an inability to finance operations and growth; (12) compliance with certain corporate and securities law requirements; and (13) other factors that are beyond the Company’s control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.

THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Newsletter Sign Up